Merz's Novabel Suspended In EU, Pausing New Business Strategy
This article was originally published in The Gray Sheet
Executive Summary
U.K authorities told health care professionals and aesthetic practitioners on August 12 not to use Merz Pharmaceuticals' dermal filler Novabel (alginate) because of a potential association with skin nodules and induration, particularly in the infra-orbital area, and to return all unused product to the company
You may also be interested in...
Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition
Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.